Dermagnostix develops a molecular diagnostic platform that utilizes automated microfluidics technology to differentiate between psoriasis and eczema within 45 minutes to 2 hours. This system addresses the need for precise diagnostics in dermatology, enabling timely and objective treatment decisions for patients with inflammatory skin diseases.
Funding
$8.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Distinguishing between psoriasis and eczema can be challenging due to overlapping clinical features, leading to delayed or inappropriate treatment decisions. Current diagnostic methods often lack the precision needed for timely and objective differentiation, impacting patient outcomes and healthcare costs.
Solution
Dermagnostix offers a molecular diagnostic platform that automates the differentiation between psoriasis and eczema. The system utilizes microfluidics technology to analyze patient samples, providing results within 45 minutes to 2 hours. This rapid turnaround enables clinicians to make informed treatment decisions at the point of need. The platform's objective and precise results support personalized care for patients with inflammatory skin diseases, improving diagnostic accuracy and treatment effectiveness.
Target Audience
The primary target audience includes dermatologists, dermatopathologists, and clinical laboratories seeking precise and rapid diagnostic tools for inflammatory skin diseases.
Features
- Automated microfluidics technology for sample processing and analysis
- Rapid results in 45 minutes to 2 hours, enabling timely clinical decisions
- Objective and precise molecular differentiation of psoriasis and eczema
- Portable analyzer for point-of-need diagnostics
- LabDisk containing pre-loaded reagents and materials
- Simple workflow: sample into LabDisk, LabDisk into Analyzer, answer out
- Developed and manufactured in Germany